Quick Answer
Fulcrum Therapeutics, Inc. reported Cash and Equivalents of $197.53 million for fiscal year 2025.
Fulcrum Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $197.53M | +239.3% |
| 2024 | $58.21M | +127.7% |
| 2023 | $25.56M | -27.2% |
| 2022 | $35.10M | -0.9% |
| 2021 | $35.41M | -37.9% |
| 2020 | $57.05M | -41.0% |
| 2019 | $96.71M | +32.9% |
| 2018 | $72.80M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $47.08M | -35.2% | +10.5% |
| June 30, 2025 | $42.59M | -50.9% | +1.0% |
| March 31, 2025 | $42.18M | +5.6% | -27.5% |
| December 31, 2024 | $58.21M | +127.7% | -19.9% |
| September 30, 2024 | $72.63M | +141.5% | -16.2% |
| June 30, 2024 | $86.70M | +155.3% | +117.0% |
| March 31, 2024 | $39.95M | +15.0% | +56.3% |
| December 31, 2023 | $25.56M | -27.2% | -15.0% |
- Fulcrum Therapeutics, Inc. showed an increase of +239.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2025 period, Fulcrum Therapeutics, Inc.’s cash and equivalents has grown by 171.3% (from $72.80 million to $197.53 million).
- The most recent figure is from Fulcrum Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: